ClinicalTrials.gg
CompletedNCT03521570Updated Sep 19, 2024Results posted

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

A Phase 2 interventional study of IMRT and Nivolumab in Recurrent Head and Neck Squamous Cell Carcinoma, sponsored by Emory University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck — 11 open to participants now, 15 under way, 2 of them phase 3. Nivolumab · Squamous Cell Carcinoma of Head and Neck.

Enrollment
16th of 46
62 · median 44
Started
2018
with 7 others
Phase 2
27 of 46
10 open now
Registered
12th of 46
by date

Among the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, this one is the 16th largest by enrollment, is one of 8 that started in 2018, is one of 27 in phase 2, and was the 12th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 574 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

11 of the 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing nivolumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This phase II trial studies how well intensity-modulated radiotherapy and nivolumab work together in treating patients with head and neck squamous cell cancer that has come back. Intensity-modulation radiation therapy uses varying intensities of radiation beams to kill cancer cells and shrink tumors, thereby reducing the damage to nearby healthy tissue. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving intensity-modulated radiation therapy and nivolumab may work better at treating head and neck squamous cell cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. To assess the 1-year progression-free survival (PFS) for patients with recurrent or second primary head and neck squamous cancer treated with intensity-modulated radiation therapy (IMRT) re-irradiation with concurrent and adjuvant nivolumab.

SECONDARY OBJECTIVES:

I. Evaluate the 1-year (yr) overall survival (OS) of patients treated with re-irradiation and nivolumab.

II. Evaluate patient quality of life (QOL).

III. Evaluate patterns of failure including local, regional and distant failure rates at 1 yr.

IV. Identify and estimate the incidence rate of acute and late toxicities associated with combined re-irradiation and concurrent and adjuvant nivolumab.

TERTIARY OBJECTIVE:

I. To identify potential biomarkers related to clinical benefit to concurrent and adjuvant nivolumab and re-irradiation in patients with recurrent or second primary (RSP) head and neck squamous cell carcinoma (HNSCC).

OUTLINE:

Patients receive nivolumab intravenously (IV) over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 2 years from the beginning of radiation therapy.

03

Conditions studied

  • Recurrent Head and Neck Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field
  • of greater than 6 months
  • Patients cannot have distant and have to be candidates for curative re-irradiation
  • Patients with salivary gland tumors are excluded (patients with nasopharynx or sinonasal cancers can participate)
  • Patients with unresectable disease are eligible
  • Patients who undergo surgical resection will be allowed regardless of human papilloma virus (HPV) status provided they have one of the following criteria:

    • Positive margins on pathology
    • Evidence of extracapsular spread on nodal pathology
    • Gross residual disease on postoperative or simulation imaging
    • N2/3 disease
    • T3/4 disease
    • Multifocal perineural invasion and/or lymphovascular space invasion
  • The majority of the anticipated target volume (> 50%) must have been previously treated to ≥ 40 Gy; prior radiation therapy (RT) must have been completed > 6 months prior to initiation of IMRT reirradiation; if previous RT records are unavailable, investigators can estimate the dose to previously treated tissues based on completion notes or other treatment history
  • An (ECOG) performance score 0-2
  • Granulocytes > 1500/mm³
  • > 100,000/mm³
  • \< 1.5 mg/dl
  • Creatinine \< 1.5 mg/dl
  • No other concurrent invasive treated for the past year (localized prostate cancer or early stage skin cancer are not exclusion criteria)
  • Patients with carotid artery involvement or encasement will be allowed provided they have no symptoms related to carotid involvement
  • No prior exposure to immunotherapy agents
  • Ability to understand and the willingness to sign a written document

Exclusion criteria

Exclusion Criteria:

  • Any known factors that would pose a to receiving nivolumab
  • Recursive partitioning analysis (RPA) class III patients defined as those expected to begin reirradiation within 2 years of first course of radiation therapy AND are percutaneous endoscopic gastrostomy (PEG) dependent or have a tracheostomy (patients who have undergone total laryngectomy are not excluded)
  • Patients with
  • Prior treatment with a programmed cell death protein-1 ()/programmed death-ligand 1 (PD-L1) inhibitor
  • Female patients of must have a negative serum pregnancy test within 7 days prior to enrollment
  • Patients with primary salivary gland cancers are excluded
  • Patients who have had chemotherapy or biological therapy within 4 weeks of registration
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, disease requiring systemic , symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients who are pregnant or breast-feeding
  • Patients with known active (HIV), hepatitis (hep) B, or hep C infection
  • Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Treatment (nivolumab, IMRT)

    Patients receive nivolumab IV over 30 minutes on weeks -2, 0, 2, 4, and 6 and undergo IMRT once daily beginning on week 0 for up to 6-6.5 weeks. Beginning week 10, patients receive nivolumab IV over 30 minutes every 4 weeks for up to 10 courses in the absence of disease progression or unacceptable toxicity.

    Radiation: IMRT · Biological: Nivolumab

Interventions

  • RadiationIMRT

    Undergo intensity-modulated radiation therapy

    Also known as: Intensity-Modulated Radiation Therapy, Intensity Modulated RT, Intensity-Modulated Radiotherapy

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, MDX-1106, ONO-4538, Opdivo

06

What researchers measure

Primary outcomes

  1. Number of Participants With Progression-Free Survival (PFS)

    95% confidence interval will be estimated by Kaplan-Meier method for all participants.

    Time frame: 1 year from study start

Secondary outcomes

  1. Number of Participants With Overall Survival (OS)

    Will be assessed using Kaplan-Meier method.

    Time frame: 1 year from study start

  2. Number of Participants With Pattern of Failure

    To evaluate patterns of failure as local, regional, or distant.

    Time frame: 1 year from study start

  3. Number of Participants With Incidence of Acute Adverse Events

    Acute toxicities will be identified and their incidence rate estimated.

    Time frame: Up to 1 year from study start

  4. Number of Participants With Incidence of Late Adverse Events

    Late toxicities will be identified and their incidence rate estimated.

    Time frame: 2 years from study start

  5. Quality of Life (QOL)

    The FACT-HN (Functional Assessment of Cancer Therapy-Head and Neck) (version 4) consists of a cancer-specific questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), in addition to 12 H\&N cancer-specific items (the HN subscale).The Functional Assessment of Cancer Therapy-Head and Neck Quality of Life questionnaire may be completed by the patient using paper or electronically. FACT-HN total score ranges between 0 and 148. The higher the score, the better the QOL

    Time frame: At baseline, end of Intensity-Modulated Radiation Therapy, and weeks 18, 30, 52, and 104, baseline and month 12

07

Results

Posted Sep 19, 2024

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Nivolumab, IMRT)
Started62
Completed51
Not completed11
Withdrew: Not eligible11

Outcome measures

PrimaryNumber of Participants With Progression-Free Survival (PFS)

95% confidence interval will be estimated by Kaplan-Meier method for all participants.

Time frame:
1 year from study start
Reported as:
Count of participants · Participants
Number of Participants With Progression-Free Survival (PFS)
ParticipantsTreatment (Nivolumab, IMRT)
Number of Participants With Progression-Free Survival (PFS)27
SecondaryNumber of Participants With Overall Survival (OS)

Will be assessed using Kaplan-Meier method.

Time frame:
1 year from study start
Reported as:
Number · percentage of participants
Number of Participants With Overall Survival (OS)
percentage of participantsTreatment (Nivolumab, IMRT)
Number of Participants With Overall Survival (OS)84.4 (74.4 to 95.7)
SecondaryNumber of Participants With Pattern of Failure

To evaluate patterns of failure as local, regional, or distant.

Time frame:
1 year from study start
Reported as:
Count of participants · Participants
Number of Participants With Pattern of Failure
ParticipantsTreatment (Nivolumab, IMRT)
Number of Participants With Pattern of Failure2
SecondaryNumber of Participants With Incidence of Acute Adverse Events

Acute toxicities will be identified and their incidence rate estimated.

Time frame:
Up to 1 year from study start
Reported as:
Number · percentage of participants
Number of Participants With Incidence of Acute Adverse Events
percentage of participantsTreatment (Nivolumab, IMRT)
fatigue82.4
dermatitis58.8
dysphagia54.9
mucositis49
dry mouth47.1
Lymphopenia11.8
SecondaryNumber of Participants With Incidence of Late Adverse Events

Late toxicities will be identified and their incidence rate estimated.

Time frame:
2 years from study start
Reported as:
Count of participants · Participants
Number of Participants With Incidence of Late Adverse Events
ParticipantsTreatment (Nivolumab, IMRT)
Number of Participants With Incidence of Late Adverse Events3
SecondaryQuality of Life (QOL)

The FACT-HN (Functional Assessment of Cancer Therapy-Head and Neck) (version 4) consists of a cancer-specific questionnaire, FACT-G (Functional Assessment of Cancer Therapy - General), in addition to 12 H\&N cancer-specific items (the HN subscale).The Functional Assessment of Cancer Therapy-Head and Neck Quality of Life questionnaire may be completed by the patient using paper or electronically. FACT-HN total score ranges between 0 and 148. The higher the score, the better the QOL

Time frame:
At baseline, end of Intensity-Modulated Radiation Therapy, and weeks 18, 30, 52, and 104, baseline and month 12
Reported as:
Mean · score on a scale
Quality of Life (QOL)
score on a scaleTreatment (Nivolumab, IMRT)
Baseline68 ± 89.2
End of IMRT62.5 ± 90
Week 1862 ± 93.4
Week 3074.6 ± 101
Week 5259 ± 94.5
Week 10459 ± 94.5

Adverse events

Collected over 2 years. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Nivolumab, IMRT)24/51 (47.1%)24/51 (47.1%)51/51 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment (Nivolumab, IMRT)
DeathGeneral disorders24/51
Most frequent other events
Showing 10 of 180
Most frequent other events
EventTreatment (Nivolumab, IMRT)
FatigueGeneral disorders40/51
Dermatitis radiationInjury, poisoning and procedural complications30/51
DysphagiaGastrointestinal disorders28/51
CoughRespiratory, thoracic and mediastinal disorders28/51
Mucositis oralGastrointestinal disorders24/51
Dry mouthGastrointestinal disorders24/51
DysgeusiaNervous system disorders21/51
AnorexiaMetabolism and nutrition disorders20/51
Gastrointestinal disorders - Other, specifyGastrointestinal disorders19/51
ConstipationGastrointestinal disorders17/51

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Nivolumab, IMRT)
<=18 years0
Between 18 and 65 years31
>=65 years20
Age, Continuous
Age, Continuous(years)Treatment (Nivolumab, IMRT)
Mean62 (56 to 67)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Nivolumab, IMRT)
Female9
Male42
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Nivolumab, IMRT)
Hispanic or Latino0
Not Hispanic or Latino48
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Nivolumab, IMRT)
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American7
White39
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)Treatment (Nivolumab, IMRT)
United States51
08

Study locations

4 sites
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Froedtert and the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Jul 2022, 48 months.

Results were first posted in Sep 2024, 2 years 1 month after primary completion.

Of 298 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's 48 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2018
First posted
May 11, 2018
StartActual
Jun 28, 2018
Primary completionActual
Jul 25, 2022
CompletionActual
Sep 7, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03521570
Lead sponsor
Emory University
Responsible party
Nabil F. Saba (Principal Investigator, Emory University) — Principal investigator
First posted
May 11, 2018
Start date
Jun 28, 2018
Primary completion
Jul 25, 2022
Completion
Sep 7, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Study contacts

Nabil F. Saba, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion